News

Novo Nordisk Shares Tumble as Wegovy Copycats Weigh on Results

Novo Nordisk cut its full-year guidance as U.S. sales continue to be hurt by copycat versions of its blockbuster Wegovy ...

Novo Nordisk drops as GLP-1 headwinds prompt guidance cut; names new CEO

Novo Nordisk (NVO) stock falls as the company names a new CEO and cuts outlook citing pressure on obesity drug sales. Eli ...

Novo Nordisk names Mike Doustdar as new CEO, Chief Scientific Officer retires

Novo Nordisk (NYSE:NVO) has appointed Maziar Mike Doustdar as its new president and chief executive officer, effective August 7, 2025, the company announced on Tuesday.
Devdiscourse1d

Novo Nordisk's Wegovy: Battling Market Challenges Amid Rising Prescriptions

The U.S. FDA ban on compounded versions of Novo Nordisk's Wegovy has increased its prescriptions by 33%. Despite this, ...

Novo Nordisk's Moat Is Deeper Than You Think

Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...

Novo Nordisk Bets Big on India, creates new jobs

Novo Nordisk has launched its anti-obesity drug Wegovy in India, which has become a key market for the company. Having ...
Fierce Pharma4d

Viatris beats Novo in semaglutide patent feud, clearing hurdle for potential Wegovy generic

After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

Judge Rules Mylan Did Not Infringe Novo Nordisk Patent In Wegovy Generic Case

A federal court ruled in Mylan's favor, finding no infringement of Novo's patent tied to Wegovy, rejecting direct, ...